Smyth J F, Beattie G J, Stewart M E, Cowie V J, Smart G E, Livingstone J R, Leonard R C
University Department of Clinical Oncology, Western General Hospital, Edinburgh, UK.
Ann Oncol. 1991 Nov-Dec;2(10):755-8. doi: 10.1093/oxfordjournals.annonc.a057859.
80 patients with advanced epithelial ovarian carcinoma were treated for 6 months with cisplatinum and prednimustine following initial surgery. Response to treatment was assessed by second-look surgery. The objective response rate was 69% with 38% achieving a complete response for up to 55 months. The toxicity of this regimen was acceptable. Statistically, de-bulking or partial de-bulking had a significant beneficial effect on the likelihood of a complete response. The best survival figures were associated with maximum de-bulking. The combination of cisplatinum and prednimustine is a new and active regimen for operable advanced epithelial ovarian carcinoma.
80例晚期上皮性卵巢癌患者在初次手术后接受顺铂和泼尼氮芥治疗6个月。通过二次探查手术评估治疗反应。客观缓解率为69%，其中38%达到完全缓解，持续长达55个月。该治疗方案的毒性是可接受的。从统计学上看，肿瘤细胞减灭术或部分肿瘤细胞减灭术对完全缓解的可能性有显著的有益影响。最佳生存数据与最大程度的肿瘤细胞减灭术相关。顺铂和泼尼氮芥联合方案是治疗可手术的晚期上皮性卵巢癌的一种新的有效方案。
